NEW YORK (
CHANGE IN RATINGS
(AMAT - Get Report)
was downgraded at Needham from Buy to Hold. Estimates were also cut, given a more cautious industry outlook, Needham said.
(AMZN - Get Report)
was upgraded at Credit Suisse from Neutral to Outperform. $270 price target. Estimates were also boosted, as recent investments should pay off, Credit Suisse said.
was initiated with an Equal-Weight rating at Morgan Stanley. Valuation call, Morgan Stanley said.
was upgraded at UBS to Buy from Neutral. $45 price target. Recent decline offers buying opportunity, UBS said.
was initiated with a Market Perform at FBR Capital Markets. Valuation call, based on a $54 price target, FBR said.
was upgraded at Jefferies to Buy from Hold. $58 price target. Valuation is favorable, Dominion said.
(EAT - Get Report)
numbers were raised at UBS. Shares are now seen reaching $35. Estimates were also increased as sustainable sales warrant higher valuation, UBS said. Buy rating.
was upgraded at Bank of America/Merrill Lynch to Buy from Neutral. $8.50 price target. Structural mix shift favorable to margin profile, BofA/Merrill said.
(GRPN - Get Report)
was upgraded at Sterne Agee from Neutral to Buy. $20 price target. Company is leveraging higher sales in North America, Sterne Agee said.
Groupon was upgraded at Citigroup from Neutral to Buy. $22 price target. Company is posting higher seasonal growth, Citi said.
was upgraded at Stifel Nicolaus from Hold to Buy. Valuation call, based on a $24 price target, Stifel Nicolaus said.
was upgraded at Bank of America/Merrill Lynch to Buy from Neutral. $28 price target. History shows iPhone launches are a significant catalyst, BofA/Merrill said.
(JNPR - Get Report)
was upgraded at Bank of America/Merrill Lynch from Neutral to Buy. $25 price target. Valuation call, as the stock is down 55% over the past 12 months, BofA/Merrill said.
was upgraded at DA Davidson to Buy from Neutral. $16 price target. Earnings stabilizing, growth prospects improve, DA Davidson said.
was initiated with a Buy rating at Bank of America/Merrill Lynch. $54 price target. Company has low exposure to Medicaid and can generate 10% organic growth, BofA/Merrill Lynch said.